Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127094381 | 12709438 | 1 | I | 20160823 | 20160902 | 20160902 | EXP | US-JNJFOC-20160826162 | JANSSEN | MULLIGAN N, SCHALKWIJK S, BEST BM, COLBERS A, WANG J, CAPPARELLI EV, ET AL. ETRAVIRINE PHARMACOKINETICS IN HIV-INFECTED PREGNANT WOMEN. FRONT. PHARMACOL 04-AUG-2016;7:239. | 0.00 | Y | 0.00000 | 20160902 | OT | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127094381 | 12709438 | 1 | PS | ETRAVIRINE | ETRAVIRINE | 1 | Transplacental | MOTHER?S DOSING | N | 22187 | 200 | MG | TABLETS | BID | |||||
| 127094381 | 12709438 | 2 | SS | DARUNAVIR | DARUNAVIR | 1 | Transplacental | MOTHER?S DOSING | N | 21976 | TABLETS | ||||||||
| 127094381 | 12709438 | 3 | SS | RALTEGRAVIR. | RALTEGRAVIR | 1 | Transplacental | MOTHER?S DOSING | 0 | UNSPECIFIED | |||||||||
| 127094381 | 12709438 | 4 | SS | TRUVADA | EMTRICITABINETENOFOVIR DISOPROXIL FUMARATE | 1 | Transplacental | MOTHER?S DOSING | 0 | UNSPECIFIED | |||||||||
| 127094381 | 12709438 | 5 | SS | KALETRA | LOPINAVIRRITONAVIR | 1 | Transplacental | MOTHER?S DOSING | 0 | UNSPECIFIED | |||||||||
| 127094381 | 12709438 | 6 | SS | MARAVIROC | MARAVIROC | 1 | Transplacental | MOTHER?S DOSING | 0 | UNSPECIFIED | |||||||||
| 127094381 | 12709438 | 7 | SS | RITONAVIR. | RITONAVIR | 1 | Transplacental | MOTHER?S DOSING | 0 | UNSPECIFIED | |||||||||
| 127094381 | 12709438 | 8 | SS | COMBIVIR | LAMIVUDINEIDOVUDINE | 1 | Transplacental | MOTHER?S DOSING | 0 | UNSPECIFIED |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127094381 | 12709438 | 1 | HIV infection |
| 127094381 | 12709438 | 2 | HIV infection |
| 127094381 | 12709438 | 3 | HIV infection |
| 127094381 | 12709438 | 4 | HIV infection |
| 127094381 | 12709438 | 5 | HIV infection |
| 127094381 | 12709438 | 6 | HIV infection |
| 127094381 | 12709438 | 7 | HIV infection |
| 127094381 | 12709438 | 8 | HIV infection |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127094381 | 12709438 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127094381 | 12709438 | Blood potassium abnormal | |
| 127094381 | 12709438 | Foetal exposure during pregnancy | |
| 127094381 | 12709438 | Neutrophil count abnormal |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |